



COPY OF PAPERS
ORIGINALLY FILED

92 404/1645

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF MAILING

P#4

I hereby certify that this INFORMATION DISCLOSURE STATEMENT and documents submitted therewith are being deposited with the United States Postal Service as first class mail, postage prepaid thereon, in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date indicated below.

Nancy Malsich
Nancy Malsich

5/14/02
Date

RECEIVED
JUN 11 2002

TECH CENTER 1600/2900

Applicant: Kirkland, et al.)	
Serial No.: 09/858,279)	Group: 1645
Filed: May 15, 2001)	Examiner: Unassigned
For: MONOCLONAL ANTIBODIES IMMUNO- REACTIVE WITH LIPOPOLYSACCHARIDE BINDING PROTEIN (LBP) AND METHODS OF THEIR USE)	Our Ref.: TSRI 372.0 D2

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In recognition of its continuing duty to disclose pursuant to 37 CFR §1.56, Applicant hereby submits the present Information Disclosure Statement in compliance therewith.

Pursuant to 37 CFR §1.98(d), enclosed herewith is a copy of 1) the Information Disclosure Statement and 2) the accompanying PTO Form 1449 filed in the application 08/153,364. Application 08/153,364 was filed on November 16, 1993, and is now abandoned, to which the present application is related by division. Also, pursuant to 37 CFR §1.98(d), copies of the above references are not submitted herewith, as they are available in the related

patent application 08/153,364.

Applicants understand that the interpretation given to each reference may differ from one individual to another. The PTO is therefore encouraged to independently examine the disclosed references. While the references provided in this Information Disclosure Statement may be material pursuant to 37 CFR §1.56, it shall not be construed to be an admission that the cited information is, or is considered to be, material to patentability unless specifically designated as such.

Applicants are filing the present statement pursuant to 37 CFR §1.97(b) insofar as this statement is being filed within three months of the filing of the application and/or before the mailing date of a first Office Action.

Also, in accordance with 37 CFR §1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or, that if made, any search was complete or exhaustive, or that no other material information as defined in 37 CFR §1.56 exists.

Respectfully submitted,

5-14-02

Date

Thomas E. Northrup

Thomas E. Northrup, Reg. No. 33,268

THE SCRIPPS RESEARCH INSTITUTE
Office of Patent Counsel
10550 North Torrey Pines Road
Mail Drop TPC-8
La Jolla, CA 92037
(858) 784-2937